Physician profile
Michael Kan
NPI 1558414623
$4,128.58
in general payments reported to CMS, 2019-2025
18 companies · $725 in 2025
The $725 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $429 · 2021: $780 · 2022: $160 · 2023: $639 · 2024: $556 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.51 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,333.21 | 2019-2025 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $723.85 | 2019-2022 | |
| Lilly USA, LLC | $306.30 | 2019-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.91 | 2020-2023 | |
| Astellas Pharma US INC | $237.48 | 2024-2025 | Veozah |
| Pfizer INC. | $202.39 | 2019-2025 | |
| Novo Nordisk INC | $195.69 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.63 | 2025 | |
| Glaxosmithkline, LLC. | $140.50 | 2024 | Arexvy, Trelegy Ellipta |
| Si-Bone, INC. | $128.54 | 2023 | |
| Amgen INC. | $124.73 | 2019 | |
| Merck Sharp & Dohme LLC | $110.39 | 2019-2021 | |
| Bausch Health US, LLC | $59.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $51.69 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $29.59 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $25.75 | 2020 | |
| Exact Sciences Corporation | $21.30 | 2023 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $19.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.